Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 2, 2017, Pages

  Temkin, Elizabeth ^a   Torre Cisneros, Julian ^i,j   Beovic, Bojana ^b   Benito, Natividad ^c,d   Giannella, Maddalena ^e   Gilarranz, Raúl ^f   Jeremiah, Cameron ^g   Loeches, Belén ^h   MacHuca, Isabel ^i,j   Jiménez Martín, María José ^k   Martínez, José Antonio ^l   Mora Rillo, Marta ^h   Navas, Enrique ^m   Osthoff, Michael ⁿ   Pozo, Juan Carlos ⁱ   Ramos, Juan Carlos Ramos ^h   Rodriguez, Marina ⁱ   Sánchez García, Miguel ^k   Viale, Pierluigi ^o   Wolff, Michel ^p,q   Carmeli, Yehuda ^a,r   more..

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g ST VINCENT S HOSPITAL   (Australia)

^h HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j UNIVERSITY OF CÓRDOBA   (Spain)

^k HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^l UNIVERSITY OF BARCELONA   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^o UNIVERSITY OF BOLOGNA   (Italy)

^p BICHAT HOSPITAL   (France)

^q UNIVERSITÉ PARIS DESCARTES   (France)

^r TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

Carbapenem resistance; Case series; Ceftazidime avibactam

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; TIGECYCLINE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BRAIN VENTRICULITIS; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL ARTICLE; COMPASSIONATE USE; DRUG TREATMENT FAILURE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL INFECTION; HOSPITAL MORTALITY; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MONOTHERAPY; MUCOSA INFLAMMATION; OSTEOMYELITIS; PRESCRIPTION; PRIORITY JOURNAL; PROSTHESIS INFECTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SALVAGE THERAPY; SKIN INFECTION; SOFT TISSUE INFECTION; SUBDURAL EMPYEMA; SURGICAL INFECTION; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PATHOGENICITY;

AGED; ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; CARBAPENEMS; CEFTAZIDIME; ENTEROBACTERIACEAE; FEMALE; HUMANS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; SALVAGE THERAPY;

EID: 85011085656     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01964-16     Document Type: Article

References (37)

1. U.S. Food and Drug Administration. 26 February 2015. FDA approves new antibacterial drug Avycaz. FDA news release. U.S. FDA, Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm435629.htm. Accessed 13 September 2016.
2. Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens PR, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, III, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/βlactamase inhibitor combination. Drugs 73:159-177. https://doi.org/10.1007/ s40265-013-0013-7.
3. van Duin D, Bonomo RA. 2016. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis 63:234-241. https://doi.org/ 10.1093/cid/ciw243.
4. Castanheira M, Mills JC, Costello SE, Jones RN, Sader HS. 2015. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamaseproducing strains. Antimicrob Agents Chemother 59:3509-3517. https:// doi.org/10.1128/AAC.00163-15.
5. Sader HS, Castanheira M, Farrell DJ, Flamm RK, Jones RN. 2015. Ceftazidime-avibactam activity when tested against ceftazidimenonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from United States medical centers (2011-2014). Diagn Microbiol Infect Dis 83:389-394. https://doi.org/10.1016/ j.diagmicrobio.2015.06.008.
6. Dupont H, Gaillot O, Goetgheluck AS, Plassart C, Emond JP, Lecuru M, Gaillard N, Derdouri S, Lemaire B, Girard de Courtilles M, Cattoir V, Mammeri H. 2015. Molecular characterization of carbapenemnonsusceptible enterobacterial isolates collected during a prospective interregional survey in France and susceptibility to the novel ceftazidime-avibactam and aztreonam-avibactam combinations. Antimicrob Agents Chemother 60:215-221. https://doi.org/10.1128/ AAC.01559-15.
7. Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C. 2012. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28:1921-1931. https://doi.org/10.1185/03007995.2012.748653.
8. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68:1183-1192. https://doi.org/10.1093/jac/dks523.
9. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. 2016. Efficacy and safety of ceftazidimeavibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62:1380-1389. https://doi.org/10.1093/cid/ciw133.
10. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. 2016. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63:754-762. https://doi.org/10.1093/cid/ciw378.
11. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. 2016. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intraabdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16:661-673. https://doi.org/10.1016/ S1473-3099(16)30004-4.
12. Mendes RE, Castanheira M, Woosley LN, Costello SE, Stone GG, Flamm RK, Jones RN. 2015. β-Lactamase characterization of baseline Enterobacteriaceae (ENT) from a phase 3 trial of ceftazidime-avibactam (CAZ-AVI) for the treatment of infections caused by CAZ-nonsusceptible (NS) pathogens, abstr 1176. Abstr IDWeek 2015, San Diego, CA. https:// idsa.confex.com/idsa/2015/webprogram/Paper53048.html. Accessed 13 September 2016.
13. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, Lopez-Cerero L, Pascual A, Natera C, Rodriguez M, Salcedo I, Rodriguez-Lopez F, Rivero A, Rodriguez-Bano J. 2015. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 70:905-913. https://doi.org/10.1093/ jac/dku432.
14. Actavis. 2015. Avycaz package insert. Actavis, Parsippany, NJ. http:// www.allergan.com/assets/pdf/avycaz-pi. Accessed 13 September 2016.
15. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenemresistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62:165-170.
16. European Centre for Disease Prevention and Control. 2016. Antimicrobial resistance interactive database (EARS-Net). http://ecdc.europa.eu/ en/healthtopics/antimicrobial-resistance-and-consumption/ antimicrobial-resistance/database/Pages/database.aspx. Accessed 13 September 2016.
17. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654-663. https://doi.org/10.1128/ AAC.01222-13.
18. Pogue JM, Ortwine JK, Kaye KS. 2015. Optimal usage of colistin: are we any closer? Clin Infect Dis 61:1778-1780. https://doi.org/10.1093/cid/ civ723.
19. van Duin D, Doi Y. 2015. Outbreak of colistin-resistant, carbapenemaseproducing Klebsiella pneumoniae: are we at the end of the road? J Clin Microbiol 53:3116-3117. https://doi.org/10.1128/JCM.01399-15.
20. Dafopoulou K, Zarkotou O, Dimitroulia E, Hadjichristodoulou C, Gennimata V, Pournaras S, Tsakris A. 2015. Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 59:4625-4630. https://doi.org/10.1128/ AAC.00868-15.
21. Cprek JB, Gallagher JC. 2015. Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 60:669-673. https://doi.org/10.1128/AAC.01569-15.
22. Camargo JF, Simkins J, Beduschi T, Tekin A, Aragon L, Perez-Cardona A, Prado CE, Morris MI, Abbo LM, Canton R. 2015. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 59:5903-5908. https:// doi.org/10.1128/AAC.00655-15.
23. Villegas MV, Pallares CJ, Escandon-Vargas K, Hernandez-Gomez C, Correa A, Alvarez C, Rosso F, Matta L, Luna C, Zurita J, Mejia-Villatoro C, Rodriguez-Noriega E, Seas C, Cortesia M, Guzman-Suarez A, Guzman-Blanco M. 2016. Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American countries. PLoS One 11:e0154092. https://doi.org/ 10.1371/journal.pone.0154092.
24. Balkan II, Aygun G, Aydin S, Mutcali SI, Kara Z, Kuşkucu M, Midilli K, Şemen V, Aras S, Yemişen M, Mete B, Ozaras R, Saltoǧlu N, Tabak F, Ozturk R. 2014. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 26:51-56. https://doi.org/10.1016/j.ijid.2014.05.012.
25. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, Maor Y, Rahav G. 2012. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 18:54-60. https://doi.org/ 10.1111/j.1469-0691.2011.03478.x.
26. Chang HJ, Hsu PC, Yang CC, Kuo AJ, Chia JH, Wu TL, Lee MH. 2011. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect 44:125-130. https://doi.org/10.1016/j.jmii.2010.06.001.
27. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P, ISGRI-SITA (Italian Study Group on Resistant Infections of the Societa Italiana Terapia Antinfettiva). 2015. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70: 2133-2143. https://doi.org/10.1093/jac/dkv086.
28. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. https://doi.org/10.1128/ AAC.02166-13.
29. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597-1606. https:// doi.org/10.1093/jac/dks121.
30. Lagace-Wiens P, Walkty A, Karlowsky JA. 2014. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 9:13-25. https://doi.org/10.2147/CE.S40698.
31. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH. 13 September 2016. Clinical outcomes, drug toxicity and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis pii: ciw636. Epub ahead of print.
32. Livermore DM, Warner M, Jamrozy D, Mushtaq S, Nichols WW, Mustafa N, Woodford N. 2015. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase. Antimicrob Agents Chemother 59:5324-5330. https://doi.org/10.1128/AAC.00678-15.
33. Wu G, Abraham T, Lee S. 2016. S. Ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 63: 1147-1148. https://doi.org/10.1093/cid/ciw491.
34. Rashid MU, Rosenborg S, Panagiotidis G, Lofdal KS, Weintraub A, Nord CE. 2015. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents 46:60-65. https:// doi.org/10.1016/j.ijantimicag.2015.02.027.
35. Grill MF, Maganti R. 2008. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 42:1843-1850. https://doi.org/10.1345/aph.1L307.
36. Rosenblatt M, Kuhlik B. 2015. Principles and challenges in access to experimental medicines. JAMA 313:2023-2024. https://doi.org/10.1001/ jama.2015.4135.
37. McCabe WR, Jackson GG. 1962. Gram negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:845-847.